Telix Pharmaceuticals Limited (TLX) AI Stock Analysis

Telix Pharmaceuticals Limited develops and commercializes therapeutic and diagnostic radiopharmaceuticals across three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate in Phase 3 clinical trials for advanced prostate cancer. The company also develops TLX250 and TLX252 for advanced metastatic kidney cancer, TLX101 and TLX102 for glioblastoma, and Illuccix and Gozellix for prostate cancer treatment. Additional pipeline programs include TLX66 for bone marrow conditioning, TLX400 for bladder tumors, TLX300 for soft tissue sarcoma, and diagnostic assets such as BiPASS and TLX250-Px.

Telix expanded annual revenue from $7.6M in FY2021 to $1.21B in FY2025, representing a 53.9% increase over FY2024. Gross margin compressed from 66.5% in FY2021 to 53.1% in FY2025. After posting net income of $49.9M and an operating margin of 10.5% in FY2024, the company recorded a net loss of -$10.7M and an operating margin of 2.2% in FY2025, driven partly by R&D expenses rising to $256.8M. For the latest quarter ended June 30, 2026, quarterly revenue grew 22.3% year-over-year, bringing trailing twelve-month revenue to $890.8M with an operating margin of 9.7% and a profit margin of 3.8%.

As of June 30, 2026, Telix held $363.6M in cash and short-term investments against $837.0M in total debt, resulting in net debt of $473.4M and a debt-to-equity ratio of 1.19. Total assets stood at $1.97B compared to shareholders' equity of $704.0M, supported by a current ratio of 2.01. Operating cash flow fell to -$25.9M in FY2025, leading to free cash flow of -$82.8M after capital expenditures of $56.9M. Over the past five years, the company's share count increased by 26.1%.

Telix trades at a trailing P/E of 106.9x and a forward P/E of 140.8x, compared to medians of 24.6x and 17.3x, respectively, for its US-listed Healthcare peers. Its enterprise value of $4.21B reflects an EV-to-EBITDA multiple of 58.1x, above the peer median of 12.0x, while its price-to-sales ratio matches the peer median at 4.1x. Over the past year, TLX shares returned -1.6%, lagging the S&P 500's return of 16.8%, though the stock has gained 42.7% year-to-date through October 16, 2026.

All 5 analyst ratings on Telix are Strong Buy. The mean price target is $20.57, which is 92.4% above the last close of $10.69 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.39B and EPS of $0.15, indicating 599.0% EPS growth. For the following fiscal year, 2 analysts project revenue of $1.58B and EPS of -$0.04. Over the last four quarters, Telix has beaten EPS estimates 2 times.

This page is an AI-written research summary of Telix Pharmaceuticals Limited (TLX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TLX income statement, TLX balance sheet, TLX key metrics, TLX analyst forecast, TLX chart. See the TLX stock overview for the latest quote and news.